Hirotaka Matsui

Chuo, 1040045, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 111 publications

Response to comments on "Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan".

Response to comments on "Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan".

Journal: International journal of hematology

Published: June 18, 2026

T-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucel.

T-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucel.

Journal: International journal of hematology

Published: January 19, 2026

Real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and/or bridging therapy in relapsed/refractory primary mediastinal large B-cell lymphoma.

Real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and/or bridging therapy in relapsed/refractory primary mediastinal large B-cell lymphoma.

Journal: International journal of clinical oncology

Published: January 09, 2026

Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan.

Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan.

Journal: International journal of hematology

Published: October 21, 2025

Genotype-integrated single-cell transcriptome analysis reveals the role of DDX41 pR525H in a patient with myelodysplastic neoplasms.

Genotype-integrated single-cell transcriptome analysis reveals the role of DDX41 pR525H in a patient with myelodysplastic neoplasms.

Journal: Scientific reports

Published: April 09, 2025

Oral beclomethasone dipropionate therapy and prognostic plasma biomarkers for gastrointestinal graft-versus-host disease.

Oral beclomethasone dipropionate therapy and prognostic plasma biomarkers for gastrointestinal graft-versus-host disease.

Journal: International journal of hematology

Published: January 17, 2025

Significance of Body Surface Area Correction for Cisplatin Eligibility Based on Renal Function of Patients With Muscle-Invasive Bladder Cancer.

Significance of Body Surface Area Correction for Cisplatin Eligibility Based on Renal Function of Patients With Muscle-Invasive Bladder Cancer.

Journal: Clinical genitourinary cancer

Published: August 05, 2024

Treatment-related skin reactions in enfortumab vedotin as a surrogate marker of survival and treatment response.

Treatment-related skin reactions in enfortumab vedotin as a surrogate marker of survival and treatment response.

Journal: International journal of clinical oncology

Published: July 11, 2024

DDX41 and its unique contribution to myeloid leukemogenesis.

DDX41 and its unique contribution to myeloid leukemogenesis.

Journal: Oncotarget

Published: July 02, 2024

Myeloid/natural killer (NK) cell precursor acute leukemia as a distinct leukemia type.

Myeloid/natural killer (NK) cell precursor acute leukemia as a distinct leukemia type.

Journal: Science advances

Published: December 13, 2023

The kappa/lambda ratio of surface immunoglobulin light chain as a valuable parameter for MRD assessment in CLL with atypical immunophenotype.

The kappa/lambda ratio of surface immunoglobulin light chain as a valuable parameter for MRD assessment in CLL with atypical immunophenotype.

Journal: Scientific reports

Published: December 06, 2023

Evaluation of the pathogenic potential of germline DDX41 variants in hematopoietic neoplasms using the ACMG/AMP guidelines.

Evaluation of the pathogenic potential of germline DDX41 variants in hematopoietic neoplasms using the ACMG/AMP guidelines.

Journal: International journal of hematology

Published: November 20, 2023

Showing 1-12 of 111

Last Updated: 09/26/2026